CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Gemcitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00660699
NCT00660699Phase 2Completed
CompareCT.gov

A Feasibility Phase II Study of Gemcitabine With Docetaxel With Concurrent 3-D Conformal Radiation Plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

Washington University School of Medicine·interventional·Posted Apr 17, 2008·Updated May 27, 2015

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, Docetaxel, and 1 other intervention for Cholangiocarcinoma Cancer and 3 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2008
Enrollment StartSep 1, 2002
Primary CompletionSep 1, 2010
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 18.2 years ago

Interventions

Gemcitabinedrug

Docetaxeldrug

Radiationradiation